Moran Wealth Management LLC raised its holdings in Danaher Co. (NYSE:DHR – Free Report) by 2.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,413 shares of the conglomerate’s stock after purchasing an additional 58 shares during the period. Moran Wealth Management LLC’s holdings in Danaher were worth $554,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. FMR LLC increased its holdings in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Danaher in the 4th quarter worth approximately $391,172,000. Van ECK Associates Corp increased its holdings in shares of Danaher by 6,862.7% in the 4th quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after acquiring an additional 916,513 shares during the last quarter. Proficio Capital Partners LLC raised its position in shares of Danaher by 29,287.7% during the 4th quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock valued at $135,189,000 after acquiring an additional 586,925 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 11.10% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on Danaher
Danaher Stock Down 0.2 %
DHR stock opened at $205.24 on Thursday. The company has a 50 day moving average of $221.06 and a two-hundred day moving average of $241.48. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a market cap of $146.69 billion, a price-to-earnings ratio of 38.87, a PEG ratio of 2.66 and a beta of 0.82.
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the company earned $2.09 EPS. On average, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. Danaher’s payout ratio is 24.24%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- 3 Stocks to Consider Buying in October
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Why Energy Transfer Belongs on Your Watchlist
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.